Amarantus Announces Issuance of United States Patent No. 9,066,903 Covering Proprietary Methods of Administration of Eltoprazine for the Treatment of Parkinson's Disease

Patent Provides IP Protection for Lead Product Candidate Eltoprazine for the Treatment of Parkinson’s Disease SAN FRANCISCO and GENEVA, June 30, 2015 (GLOBE NEWSWIRE) — Amarantus BioScience Holdings,…Read More »

Amarantus Announces Presentation of Eltoprazine Phase 1/2a Clinical Data at the 19th International Congress of Parkinson's Disease and Movement Disorders

- Poster Presentation on June 15, 2015 from 12:30-2:00 p.m. PDT – SAN FRANCISCO and GENEVA, June 15, 2015 (GLOBE NEWSWIRE) — Amarantus BioScience Holdings, Inc. (OTCQB:AMBSD), a biotechnology company…Read More »

Amarantus to Present at the BIO International Convention

Presentation With Live Webcast on June 16, 2015 at 2:30 p.m. EDT to Focus Primarily on Eltoprazine Phase 2b Clinical Study Initiation and Amarantus Diagnostics SAN FRANCISCO and GENEVA, June 10, 2015…Read More »

Amarantus Completes Capital Restructuring in Preparation for National Exchange Listing

SAN FRANCISCO and GENEVA, June 9, 2015 (GLOBE NEWSWIRE) — Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neuro…Read More »

Amarantus Diagnostics Announces Acceptance of Two Late-Breaking Abstracts on LymPro Test(R) Data at the 2015 Alzheimer's Association International Conference(R)

Amarantus Diagnostics is a Silver Sponsor of AAIC SAN FRANCISCO and GENEVA, June 9, 2015 (GLOBE NEWSWIRE) — Amarantus Diagnostics, a neurology-focused diagnostics company developing diagnostic tests…Read More »
Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) is a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis (programmed cell death).

Company Information

Company Website: http://www.amarantus.com/
Company Headquarters

Amarantus BioScience Holdings, Inc.
655 Montgomery Street
Suite 900
San Francisco, CA 94111
Phone: (415) 688-4484
Fax: (408) 852-4427
info@amarantus.com

Media and Investor Relations Contact

Jenene Thomas Communications, LLC
Jenene Thomas, Investor Relations and Corporate Communications Advisor
Phone: (908) 938-1475
jenene@jenenethomascommunications.com

Forward Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

This Blog is official and sanctioned by Amarantus BioScience | See Disclaimer | See Privacy Policy

Get Amarantus BioScience Blog Post Alerts